Ascendis Pharma AS logo
ASNDAscendis Pharma AS
Trade ASND now
Ascendis Pharma AS primary media

About Ascendis Pharma AS

Ascendis Pharma (NASDAQ:ASND) is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs. The company's operations are centered on its proprietary TransCon technology, which enables the creation of new and improved versions of existing drugs, aiming to provide enhanced clinical efficacy, safety, and patient experience. Ascendis has a diverse portfolio of projects, spanning areas such as endocrinology, oncology, and other major therapeutic fields. Its objective is to leverage its technology platform to build a leading, sustainable biopharma company that brings meaningful improvements to patients' lives worldwide.

What is ASND known for?

Snapshot

Public US
Ownership
2006
Year founded
913
Employees
Hellerup, Denmark
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Kingdom of Denmark

Produtos e/ou serviços de Ascendis Pharma AS

  • TransCon hGH, a long-acting growth hormone for children and adults with growth hormone deficiency.
  • TransCon PTH, a prodrug of parathyroid hormone for hypoparathyroidism treatment.
  • TransCon CNP, a therapy aimed at treating achondroplasia and potentially other fibroblast growth factor receptor-related skeletal disorders.
  • Skytrofa (lonapegsomatropin-tcgd), approved in the US and EU for pediatric growth hormone deficiency, offers once-weekly dosing.
  • Vision 3x, a strategy focusing on endocrinology, oncology, and the central nervous system using TransCon technology for new therapeutics.
  • Comprehensive development programs in the field of oncology, leveraging proprietary technologies to create novel therapies.

equipe executiva do Ascendis Pharma AS

  • Mr. Jan Moller MikkelsenPresident, CEO, Member of Executive Board & Executive Director
  • Mr. Scott T. SmithCFO, Executive VP & Member of Executive Board
  • Ms. Pedersen Anni Lotte Kirstine SonderbjergExecutive VP, Chief Administrative Officer & Member of the Executive Board
  • Mr. Michael Wolff Jensen L.L.M.Executive VP, Chief Legal Officer & Member of the Executive Board
  • Mr. Mads BodenhoffSenior VP, Head of Finance & Principal Accounting Officer
  • Mr. Chad FugureVice President of Investor Relations
  • Mr. Flemming Steen JensenExecutive Vice President of Product Supply & Quality
  • Dr. Kennett Sprogoe Ph.D.Executive VP and Head of Research & Product Development
  • Dr. Stina Singel M.D., Ph.D.Executive VP & Head of Clinical Development for Oncology
  • Mr. Joseph KellyHead of U.S. Commercial of Endocrinology

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.